相关实验视频

Updated: Jul 18, 2025

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

HOXD9是一种潜在的预后生物标志物,与质瘤的免疫微环境有关

Sumei Xu^1,2, Haiyan Xiao^1,2, Tao Song³

¹Phase I Clinical Trial Center, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.

Journal of cancer research and clinical oncology

|August 21, 2023

概括

高HOXD9表达与质瘤预后不佳相关,并影响瘤免疫微环境. 这项研究确定HOXD9为质瘤患者的潜在预后生物标志物,影响生存结果.

科学领域:

神经瘤学神经瘤学
分子生物学分子生物学
癌症基因组学癌症基因组学

背景情况:

质瘤是最常见的恶性脑瘤,其发展与HOXD9有关.
对于HOXD9在质瘤发病过程中的作用的确切机制需要进一步阐明.
了解HOXD9的功能对于推进质瘤治疗策略至关重要.

研究的目的:

为了研究HOXD9在质瘤中的作用.
在质瘤进展过程中分析HOXD9表达模式.
确定HOXD9作为质瘤的潜在预后生物标志物.

主要方法:

在TCGA和CGGA质瘤数据集中对HOXD9表达的分析.
通过qRT-PCR和西式涂抹验证HOXD9mRNA和蛋白质水平.
使用生存分析,ROC曲线和名ograms进行预后评估.
使用ssGSEA和ESTIMATE算法评估HOXD9与瘤免疫微环境的关联.
识别与HOXD9相关的基因组变化.

主要成果:

在质瘤中,HOXD9的表达显著上调,与恶性特征相关.
高水平的HOXD9与患者的预后不佳和生存率降低有关.
高HOXD9表达与瘤纯度降低和免疫入侵增加相关.
HOXD9与质瘤内的基因组变化有显著联系.

结论:

HOXD9与质瘤患者的预后和生存率有显著的关联.
HOXD9显示出作为质瘤预后生物标志物的潜力.
HOXD9影响质瘤免疫微环境,提供治疗见解.

关键词:

生物信息学是一种生物信息学.生物标志物生物标志物质瘤是一种质瘤.在HOXD9中,你会看到HOXD9的颜色.免疫微环境是一个微环境.

更多相关视频

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries

Published on: March 31, 2019

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...